{"organizations": [], "uuid": "dbe6ea35dba51b3ee1ec0e8081194cd170872f7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/circassia-pharma-ma-astrazeneca/astrazeneca-to-raise-stake-in-circassia-to-up-to-19-9-pct-idUSFWN1S10BB", "country": "US", "domain_rank": 408, "title": "AstraZeneca to raise stake in Circassia to up to 19.9 pct", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.989, "site_type": "news", "published": "2018-04-24T14:22:00.000+03:00", "replies_count": 0, "uuid": "dbe6ea35dba51b3ee1ec0e8081194cd170872f7f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/circassia-pharma-ma-astrazeneca/astrazeneca-to-raise-stake-in-circassia-to-up-to-19-9-pct-idUSFWN1S10BB", "ord_in_thread": 0, "title": "AstraZeneca to raise stake in Circassia to up to 19.9 pct", "locations": [], "entities": {"persons": [{"name": "paul sandle", "sentiment": "none"}, {"name": "sarah young", "sentiment": "none"}, {"name": "duaklir", "sentiment": "none"}], "locations": [{"name": "circassia", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "tudorza", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "astrazeneca", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, British pharmaceutical company AstraZeneca said it would subscribe for more shares in Circassia by injecting cash into the respiratory drug specialist to take its stake to a maximum of 19.9 percent from 14.2 percent.\nCircassia plans to use the additional funds, up to $45 million, to pay for research and development costs which it owes to AstraZeneca under the pair’s development and commercialisation agreement, which they agreed to amend.\nAstraZeneca first invested in Circassia in March 2017, backing the company’s products, Tudorza, a bronchodilator, and Duaklir, a combination drug which is in late stage development in the United States. (Reporting by Sarah Young, Editing by Paul Sandle)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-24T14:22:00.000+03:00", "crawled": "2018-04-25T14:47:01.010+03:00", "highlightTitle": ""}